SBIR Phase I: Fourier-domain Low Coherence Interferometry (fLCI) Optical Biopsy

SBIR 第一阶段：傅里叶域低相干干涉测量 (fLCI) 光学活检

• 批准号: 0610929
• 负责人: Chongchang Mao
• 金额: --
• 依托单位: Southeast TechInventures
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0610929&HistoricalAwards=false
• 关键词: SBIR; Phase; Fourier; domain; Low

This Small Business Innovative Research (SBIR) Phase I project will develop a new instrument for the detection of early stage concern in human epithelial tissue based on a novel optical spectroscopic technique, Fourier-domain Low Coherence Interferometry (fLCl). Preliminary experiments with in vitro samples have shown that fLCl can probe nuclear morphology, a common pathological biomarker in assessing tissue health. The proposed fLCl instrument will serve as a guide to biopsy for clinicians, enabling evaluation of tissue health in situ, prior to tissue removal. Early cancer diagnosis is an enormous and steady growing market and extremely important for human health care. Traditional evaluation of potential cancer cells requires systematic tissue removal with subsequent examination by a pathologist. This has lead to many false negatives as well as false positives. The fLCl method described herein will provide a high resolution and accurate iv vivo measurement of nuclear morphology, the biomarker used for the diagnosis of pre-cancerous and cancerous tissues.

这个小型企业创新研究（SBIR）第一阶段项目将开发一种新的仪器，用于检测人类上皮组织的早期关注，基于一种新的光学光谱技术，傅立叶域低相干干涉（fLCl）。 体外样品的初步实验表明，fLCl可以探测核形态，这是评估组织健康的常见病理生物标志物。拟议的fLCl仪器将作为临床医生活检的指南，在组织切除前能够原位评价组织健康。早期癌症诊断是一个巨大且稳定增长的市场，对人类健康至关重要。 传统的潜在癌细胞的评估需要系统的组织切除，随后由病理学家进行检查。 这导致了许多假阴性和假阳性。本文所述的fLCl方法将提供核形态（用于诊断癌前和癌组织的生物标志物）的高分辨率和准确的体内测量。